Nebenwirkungen · Briviact (in Italy: Nubriveo)
Briviact 10 mg/ml solution for injection/infusion · Abschnitt 4.8 · PDF-Seite 46–47
HOS-132824 · Präparat HOS-097290
46 No specific pattern of adverse event (AE) was identified in children from 1◦month to < 4◦years of age when compared to older paediatric age groups. No significant safety information was identified indicating the increasing incidence of a particular AE in this age group. As data available in children younger than 2 years of age is limited, brivaracetam is not indicated in this age range. Limited clinical data are available in neonates.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-19T16:24:00Z · SHA-256 8b43e201402e087df36cd28aad896b8b68dd1973b788cdf0991029210330f8cc · Passage f4e3e6f15999c46841052fcabed3c739c949bdcffbaa7054594d293ba1da7897 · Zeichen 4550–4992 im Abschnitt